Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Charalampos Charalampous
Utkarsh Goel
Prashant Kapoor
Moritz Binder
Francis K. Buadi
Joselle Cook
David Dingli
Angela Dispenzieri
Amie L. Fonder
Morie A. Gertz
Wilson Gonsalves
Suzanne R. Hayman
Miriam A. Hobbs
Yi L. Hwa
Taxiarchis Kourelis
Martha Q. Lacy
Nelson Leung
Yi Lin
Rahma Warsame
Robert A. Kyle
S. Vincent Rajkumar
Shaji K. Kumar
机构：
[1] Mayo Clinic,Division of Hematology, Department of Internal Medicine
[2] Mayo Clinic,Division of Nephrology and Hypertension, Department of Internal Medicine
来源：
Blood Cancer Journal | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis K.
    Cook, Joselle
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi L.
    Kourelis, Taxiarchis
    Lacy, Martha Q.
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    [J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Comparison of daratumumab-based regimens as second-line therapy in relapsed/ refractory multiple myeloma
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi Lisa
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma M.
    Rajkumar, S. Vincent
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Cook, Joselle
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie
    Gertz, Morie
    Gonsalves, Wilson
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert
    Rajkumar, Vincent
    Kumar, Shaji
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S191 - S191
  • [4] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [5] Response Kinetics of Daratumumab-Based Regimens in Patients with Newly Diagnosed or Refractory/Relapsed Multiple Myeloma
    Wang, Jiasheng
    Arroyo-Suarez, Raul
    Tse, William
    [J]. BLOOD, 2021, 138 : 3806 - +
  • [6] Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
    Ziccheddu, Bachisio
    Giannotta, Claudia
    D'Agostino, Mattia
    Bertuglia, Giuseppe
    Saraci, Elona
    Oliva, Stefania
    Genuardi, Elisa
    Papadimitriou, Marios
    Diamond, Benjamin
    Corradini, Paolo
    Coffey, David
    Landgren, Ola
    Bolli, Niccolo
    Bruno, Benedetto
    Boccadoro, Mario
    Massaia, Massimo
    Maura, Francesco
    Larocca, Alessandra
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [7] EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    Dimopoulos, M. A.
    Weisel, K.
    Kaufman, J.
    Sonneveld, P.
    Rizzo, M.
    Xu, Y.
    Fahrbach, K.
    Gaudig, M.
    Slavcev, M.
    Dearden, L.
    Lam, A.
    [J]. HAEMATOLOGICA, 2017, 102 : 525 - 526
  • [8] THALIDOMIDE OR BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE AS SECOND-LINE THERAPY FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA: A COMPARISON OF EFFICACY AND TOXICITY
    Varettoni, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 385 - 385
  • [9] Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
    Zhang, Tian-tian
    Wang, Sen
    Wan, Ning
    Zhang, Li
    Zhang, Zugui
    Jiang, Jie
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (07) : 1122 - 1139
  • [10] Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma - A Systematic Literature Review and Network Meta-analysis
    Dimopoulos, Meletios
    Weisel, Katja
    Kaufman, Jonathan L.
    Sonneveld, Pieter
    Rizzo, Maria
    Xu, Yingxin
    Fahrbach, Kyle
    Gaudig, Maren
    Slavcev, Mary
    Lam, Annette
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E63 - E63
12345